Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: J Immunol. 2017 Oct 30;199(11):3828–3839. doi: 10.4049/jimmunol.1700426

Figure 5. Complement is important for FH6-7/hFc to reduce bacterial blood burden.

Figure 5

Human blood was infected with 2 × 105 CFU/ml S. pyogenes AP1(A) or AP18 (B), 2 × 106 CFU/ml S. pyogenes BM27.6 (C) or 2 × 107 CFU/ml S. pyogenes BMJ71 (D) treated with indicated amounts of FH6-7/hFc and incubated for up to 3h. FH6-7/hFc significantly reduces the number of bacteria compared to untreated samples for both bacterial strains binding the fusion protein (AP1(A) and AP18 (B)). FH6-7/hFc had no influence on S. pyogenes BM27.6 (C) or BMJ71 (D), since both strains do not bind the fusion proteins. (E) Human blood treated with 20μg/ml FH6-7Fc was infected with 2 × 105 CFU/ml S. pyogenes AP1. Prior to infection, samples were pretreated with compstatin and/or α-FcγRs as indicated. Mean (±SD) from at least 3 independent experiments are shown. Statistical significance of differences was calculated using 2-way ANOVA with Dunnett’s post-test (overall p value in A, B and E p<0.0001, C p=0.8247 and D p=0.4248) *, p<0.05; **, p<0.01; ***, p<0.001 and ****, p<0.0001.